Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of subjects with acute bacterial gastroenteritis.
Condition or disease
Acute Gastroenteritis in Adult Travelers
Drug: PrulifloxacinDrug: Placebo
This double-blind trial will compare the safety and efficacy of prulifloxacin versus placebo in adult travelers with acute gastroenteritis characterized by diarrhea with one or more of the following signs or symptoms: nausea, vomiting, abdominal pain or cramping, fecal urgency, moderate to severe gas-related symptoms, or tenesmus of ≤72 hours duration.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of Acute Bacterial Gastroenteritis;
Traveler from Industrialized Country;
Capable of giving Informed Consent
Fever (>100.3 degrees);
Pregnant or Breast Feeding or Not using adequate birth control;
Known or Suspected (co-)Infection with non-bacterial pathogen;
Symptoms of Gastroenteritis of >72 hours;
Concomitant antibacterial with activity against enteric bacterial pathogens;
History of IBD;
Unable/Unwilling to comply with study protocol;
> 2 doses of anti-diarrheal medication within 24 hours;